Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
M.D. Anderson Cancer Center
Thomas Jefferson University
Pfizer
Thomas Jefferson University
Mayo Clinic
Rutgers, The State University of New Jersey
Ethicon, Inc.
Wake Forest University Health Sciences
Pheon Therapeutics
National Cancer Institute (NCI)
Xemed LLC
Pfizer
SignalChem Lifesciences Corporation
Takeda
Ethicon, Inc.
Mayo Clinic
Mayo Clinic
Shasqi, Inc.
M.D. Anderson Cancer Center
University of Kentucky
Tempus AI
AstraZeneca
Mayo Clinic
Sanofi
Korea University Guro Hospital
Novartis
Galvanize Therapeutics, Inc.
Washington University School of Medicine
Lyell Immunopharma, Inc.
Formycon AG
Massachusetts General Hospital
NRG Oncology
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center
ImmunoGenesis
University of Kentucky
Faeth Therapeutics
NextCure, Inc.
Abramson Cancer Center at Penn Medicine
Black Diamond Therapeutics, Inc.
Yale University
Roswell Park Cancer Institute
Bristol-Myers Squibb
Novartis
Elevation Oncology